CADRENAL THERAPEUTICS INC (CVKD)

US1276361086 - Common Stock

11.98  +0.16 (+1.35%)

Fundamental Rating

0

We assign a fundamental rating of 0 out of 10 to CVKD. CVKD was compared to 196 industry peers in the Pharmaceuticals industry. CVKD may be in some trouble as it scores bad on both profitability and health. CVKD has a expensive valuation and it also scores bad on growth.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CVKD has reported negative net income.
CVKD had a negative operating cash flow in the past year.

1.2 Ratios

With a Return On Assets value of -860.26%, CVKD is not doing good in the industry: 98.97% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -860.26%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CVKD so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

0

2. Health

2.1 Basic Checks

2.2 Solvency

Based on the Altman-Z score of -23.17, we must say that CVKD is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -23.17, CVKD is doing worse than 86.67% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -23.17
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

A Current Ratio of 0.55 indicates that CVKD may have some problems paying its short term obligations.
The Current ratio of CVKD (0.55) is worse than 93.85% of its industry peers.
CVKD has a Quick Ratio of 0.55. This is a bad value and indicates that CVKD is not financially healthy enough and could expect problems in meeting its short term obligations.
CVKD's Quick ratio of 0.55 is on the low side compared to the rest of the industry. CVKD is outperformed by 91.79% of its industry peers.
Industry RankSector Rank
Current Ratio 0.55
Quick Ratio 0.55

More info and screens

0

3. Growth

3.1 Past

EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

CVKD is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 7.14% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-989%
EPS Next 2Y-198.5%
EPS Next 3Y-88.99%
EPS Next 5Y7.14%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CVKD. In the last year negative earnings were reported.
Also next year CVKD is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A cheap valuation may be justified as CVKD's earnings are expected to decrease with -88.99% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-198.5%
EPS Next 3Y-88.99%

More info and screens

0

5. Dividend

5.1 Amount

CVKD does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CADRENAL THERAPEUTICS INC

NASDAQ:CVKD (9/18/2024, 8:00:00 PM)

11.98

+0.16 (+1.35%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap12.82M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -860.26%
ROE N/A
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 0.55
Quick Ratio 0.55
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y-989%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y